RxDoctor Payments DataLook up a doctor →

Nicole Stivers, MD

Family Medicine · Boise, IDNPI 1558370254

Payments from drug & device makers

$7,211in general payments, 2019–2025

Across 405 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$902
  • Pfizer$894
  • AstraZeneca$718
  • Lilly USA, LLC$642
  • Novo Nordisk$530
  • Amgen$479
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,15299%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,211 in reported general payments places this provider in the 90th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$84,745
Medicare patients
181
Services billed
1,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide143$148,587
EliquisApixaban100$109,325
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$81,916
FarxigaDapagliflozin Propanediol37$50,728
JardianceEmpagliflozin34$47,502
MounjaroTirzepatide38$39,912
MyrbetriqMirabegron17$18,903
TrulicityDulaglutide13$13,814
Spiriva RespimatTiotropium Bromide18$12,398
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$11,397
Emgality PenGalcanezumab-Gnlm11$7,937
Repatha SyringeEvolocumab11$7,438
Estradiol77$6,476
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$5,496
DapagliflozinDapagliflozin Propanediol13$5,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$530$148,587143 claims
PfizerEliquis, Premarin$894$114,675111 claims
GSKTrelegy Ellipta, Anoro Ellipta$398$93,313102 claims
Boehringer IngelheimJardiance, Spiriva Respimat$243$59,90052 claims
AstraZenecaFarxiga, Breztri Aerosphere$718$56,22448 claims
Lilly USA, LLCMounjaro, Trulicity$642$53,72651 claims
Astellas Pharma US IncMyrbetriq$68$18,90317 claims
AbbVieSynthroid, Armour Thyroid$902$3,75940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 803 family medicine providers in Idaho.

Other family medicine in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →